Abstract:Local recurrence after was the main pattern of failure for esophageal squamous cell carcinoma (ESCC) receiving definitive chemoradiotherapy. There is no ideal clinical features or blood biomarkers available to predict local recurrence of ESCC. Several studies have used CT radiomics to predict survival and treatment response of ESCC receiving chemoradiotherapy. However, little is known about the role of CT radiomics in prediction of local recurrence. We intended to establish and validate a pretreatment CT radiomics nomogram for prediction of local recurrence-free survival (LRFS) in ESCC patients receiving definite chemoradiotherapy. Three hundred eleven ESCC patients receiving IMRT or VMAT based definite chemoradiotherapy (232 in training and 79 in validation cohort) between February 2009 and June 2015 were enrolled. 2338 radiomics features were extracted from pretreatment contrast-enhanced computed tomography (CT) images of the primary tumor volume. Least absolute shrinkage and selection operator (LASSO) regression was used to select features for the radiomics signature. A radiomics nomogram was established by integrating the clinical data and radiomics signature. Nomogram discrimination and calibration were evaluated. The radiomics signature consisting of 4 selected features from contrast-enhanced CT images showed good prognostic performance in terms of predicting LRFS in two cohorts. Radiomics signature could stratify patients into high and low-risk group with different prognosis. Low-risk groups defined by radiomics signature (radscore cutoff value: -0.1152) had significant better LRFS than high-risk groups in training (p<0.001; 2-y LRFS 87.5% vs 46.6%; 3-y LRFS 82.5% vs 45.74%) and validation cohorts (p<0.05; 2-y LRFS 73.1% vs 54.4%; 3-y LRFS 73.1% vs 50.5%), respectively. Similarly, survival analysis also showed Low-risk groups defined by the same radiomics signature had significant better OS than high-risk groups in training (p<0.001; 2-y OS 69.3% vs 42%; 3-y OS 57.8% vs 35.6%) and validation cohorts (p<0.05; 2-y OS 51.9% vs 48.1%; 3-y OS 51.9% vs 33.4%), respectively. The radiomics nomogram established by integrating the radiomics signature with clinical data outperformed clinical nomogram alone (C-index in validation cohort, 0.68vs 0.624; P< 0.01). Calibration curves showed good agreement. The most optimal predictive power for evaluating LRFS could be achieved when radiomics signature was added to the clinical data. Pretreatment contrast-enhanced CT radiomics could be helpful for personalized risk stratification and treatment in ESCC patients receiving definitive chemoradiotherapy.

CT-based Radiomic Analysis for Prediction of Treatment Response of Salvage Chemoradiotherapy for Loco-regional Lymph Node Recurrence After Curative Esophagectomy

Computed Tomography-Based Radiomic Analysis for Prediction of Treatment Response to Salvage Chemoradiotherapy for Locoregional Lymph Node Recurrence after Curative Esophagectomy.

CT Radiomics Based on Machine Learning Predicting Pathologic Complete Response after Neoadjuvant Chemoradiotherapy for Esophageal Cancer

CT-Based Radiomics Nomogram May Predict Local Recurrence-free Survival in Esophageal Squamous Cell Carcinoma Patients Receiving Definitive Chemoradiotherapy: A Multicenter Study

Radiomics Signature Based on Support Vector Machines for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

CT Radiomics Features to Predict Lymph Node Metastasis in Advanced Esophageal Squamous Cell Carcinoma and to Discriminate Between Regional and Non-Regional Lymph Node Metastasis: a Case Control Study

CT Radiomics to Predict Pathologic Complete Response after Neoadjuvant Immunotherapy Plus Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

CT-based radiomics for predicting radio-chemotherapy response and overall survival in nonsurgical esophageal carcinoma

CT-based deep learning radiomics and hematological biomarkers in the assessment of pathological complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma: A two-center study

CT-based Radiomics Nomogram May Predict Local Recurrence-Free Survival in Esophageal Cancer Patients Receiving Definitive Chemoradiation or Radiotherapy: A Multicenter Study.

On Predicting Clinical Response to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Additional Evaluation by Magnetic Resonance Imaging May Help

A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma

Radiomics nomogram combined with clinical factors for predicting pathological complete response in resectable esophageal squamous cell carcinoma

ASO Visual Abstract: Radiomics Nomogram with Added Nodal Features Improves Treatment Response Prediction in Locally Advanced Esophageal Squamous Cell Carcinoma—A Multicenter Study

Preoperative CT Radiomics of Esophageal Squamous Cell Carcinoma and Lymph Node to Predict Nodal Disease with a High Diagnostic Capability.

Predicting Lymph Node Metastasis Using Computed Tomography Radiomics Analysis in Patients with Resectable Esophageal Squamous Cell Carcinoma

Baseline CT radiomics features to predict pathological complete response of advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy using paclitaxel and cisplatin

Using clinical and radiomic feature–based machine learning models to predict pathological complete response in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation

Pre-Treatment Computed Tomography Radiomics for Predicting the Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Retrospective Study

The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy

Radiomics Signature Facilitates Organ-Saving Strategy in Patients with Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy.